Oncology News

From 1999 to 2016, all-cause mortality among adults aged between 25 years and 64 years in many different ethnic groups in the United States increased while life expectancy in the United States plateaued from 2010 to 2016, according to two studies published in BMJ.

The FDA recently approved a thrombocytopenia therapy for adults with chronic liver disease and a combination therapy for advanced metastatic hepatocellular carcinoma. Along with these advancements, multiple societies have recently provided grants or investments into liver disease research.

Noninvasive focused ultrasound hyperthermia enhanced intratumoural delivery of doxorubicin among patients with liver tumors, according to study results published in The Lancet Oncology.

The American Association for the Study of Liver Diseases Foundation announced its investment of $4.06 million in research and career development grants awarded to 36 researchers and clinicians, according to a press release.

Harboring a BRAF V600E mutation appeared associated with a poorer prognosis and greater risk for recurrence after curative-intent resection compared with KRAS mutations among patients with colorectal cancer and liver metastasis, according to study results.

Results of a recent study provided continued confirmation that increased rates of hepatocellular carcinoma among patients treated with direct-acting antivirals compared with interferon correlated with patient characteristics such as age and liver function rather than treatment.

Cirrhosis-related mortality increased in the U.S. since 2009 with rates varying by age, ethnicity and region, according to a recently published report.

Liver cancer mortality increased from the ninth leading cause of cancer death in 2000 to sixth leading cause in 2016, according to a report published by the CDC.

The FDA granted breakthrough therapy designation to atezolizumab in combination with bevacizumab as a first-line treatment for patients with advanced metastatic hepatocellular carcinoma.

Patients with liver disease such as viral hepatitis and nonalcoholic fatty liver disease with cirrhosis are at increased risk for progression to hepatocellular carcinoma, which can also lead to extrahepatic cancer. Researchers have recently published new data on factors that improve early detection and diagnosis, as well as defining risks prior to HCC and during treatment.